Compare Crispr Therapeutics AG (CRSP) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Nutrien Ltd — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Nutrien Ltd trades at $67.48 (market cap $33.31B). The key difference: Nutrien Ltd is far larger — about 6.8× Crispr Therapeutics AG's market cap, and Nutrien Ltd pays a 3.15% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Nutrien Ltd for 59 Days on average.
| CRSP | NTR | |
|---|---|---|
Market Cap | $4.88B | $33.31B |
Volume | 2,861,747 | 1,330,729 |
Sector | Health | Basic Materials |
52-Week High | $73.97 | $83.94 |
52-Week Low | $44.34 | $53.64 |
Typical Hold Time | 77 Days | 59 Days |
Enterprise Value | $3.30B | $45.11B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
Nutrien (NTR) trades at $69.87, down 0.14% with bearish technical signals despite recent earnings beats. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.51 versus $0.48, though Q2 2026 missed at $2.61. Revenue trends show recovery from $26.0B in 2024 to $26.9B in 2025, with net income margin improving to 8.44%. Recent news highlights mixed sentiment with stock volatility following geopolitical fertilizer developments.
The outlook remains cautiously optimistic with analyst consensus at $76.14 target (8.9% upside) and 60.6% buy ratings. Key opportunities include strong potash demand and cost discipline, while risks involve fertilizer price volatility and competitive pressures from potential Belarus deals. Cash flow trends show consistent operational strength despite negative net flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
